The UK Patents Court upheld the validity of Wyeth’s patent EP(UK) 2,343,308 relating to a combination product comprising a 2086 protein and a PorA protein used in meningitis B vaccines, rejecting GSK’s allegations of lack of entitlement to two of the claimed priority dates, lack of novelty, obviousness (both conventional and so-called “AgrEvo” obviousness), insufficiency and added matter.  The court also held that a number of the claims were infringed by GSK’s meningitis B vaccine, Bexsero.

A full summary of this case has been published on Kluwer IP Law.


To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law
This page as PDF